Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy).

Fusco V, Galassi C, Berruti A, Ortega C, Ciuffreda L, Scoletta M, Goia F, Migliario M, Baraldi A, Boccadoro M, Loidoris A, Bertetto O.

ISRN Oncol. 2013;2013:672027. doi: 10.1155/2013/672027. Epub 2013 Feb 27.

2.

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E.

Ann Oncol. 2009 Jan;20(1):137-45. doi: 10.1093/annonc/mdn526. Epub 2008 Jul 22.

PMID:
18647964
3.

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.

J Clin Oncol. 2005 Dec 1;23(34):8580-7.

PMID:
16314620
4.

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G; Gruppo Italiano Studio Linfomi.

Leuk Lymphoma. 2007 Jan;48(1):56-64.

PMID:
17325848
5.

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN.

J Bone Miner Res. 2008 Jun;23(6):826-36. doi: 10.1359/jbmr.080205.

6.

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A.

Haematologica. 2006 Jul;91(7):968-71. Epub 2006 Jun 1.

7.

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.

Fusco V, Porta C, Saia G, Paglino C, Bettini G, Scoletta M, Bonacina R, Vescovi P, Merigo E, Lo Re G, Guglielmini P, Di Fede O, Campisi G, Bedogni A.

Clin Genitourin Cancer. 2015 Aug;13(4):287-94. doi: 10.1016/j.clgc.2014.12.002. Epub 2014 Dec 9. Review.

PMID:
25586958
8.

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.

Cafro AM, Barbarano L, Nosari AM, D'Avanzo G, Nichelatti M, Bibas M, Gaglioti D, Taroni A, Riva F, Morra E, Andriani A.

Clin Lymphoma Myeloma. 2008 Apr;8(2):111-6. Erratum in: Clin Lymphoma Myeloma. 2008 Aug;8(4):260. Barbarano, Luciana [added]; Nosari, Anna Maria [added]; D'Avanzo, Giovanna [added]; Nichelatti, Michele [added]; Bibas, Michele [added]; Gaglioti, Domenico [added]; Taroni, Alberto [added]; Riva, Francesco [added]; Morra, Enrica [added]; Andriani, Alessandro [added].

PMID:
18501105
9.

Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions.

Ripamonti CI, Maniezzo M, Boldini S, Pessi MA, Mariani L, Cislaghi E.

J Bone Oncol. 2012 Sep 24;1(3):81-7. doi: 10.1016/j.jbo.2012.08.001. eCollection 2012 Dec.

10.

Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.

Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G.

Oral Oncol. 2008 Sep;44(9):857-69. doi: 10.1016/j.oraloncology.2007.11.012. Epub 2008 Feb 20.

PMID:
18282788
11.

Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.

J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5.

PMID:
19805682
12.

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.

Pavkovic M, Petrushevska G, Jovanovic R, Karanfilski O, Cevreska L, Stankovic S, Stojanovic A.

Prilozi. 2010;31(2):39-49.

PMID:
21258276
13.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Mavrokokki T, Cheng A, Stein B, Goss A.

J Oral Maxillofac Surg. 2007 Mar;65(3):415-23.

PMID:
17307586
14.
15.

Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.

J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31.

PMID:
17577497
16.

Bisphosphonates and osteonecrosis of the jaw: a retrospective study.

Murad OM, Arora S, Farag AF, Guber HA.

Endocr Pract. 2007 May-Jun;13(3):232-8.

PMID:
17599853
17.

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.

Eur Urol. 2008 Nov;54(5):1066-72. doi: 10.1016/j.eururo.2008.06.070. Epub 2008 Jun 26.

PMID:
18602738
18.

[Bisphosphonates and osteonecrosis of the jaws].

Urade M.

Clin Calcium. 2007 Feb;17(2):241-8. Review. Japanese.

PMID:
17272882
19.

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A.

Ann Oncol. 2009 Jan;20(1):117-20. doi: 10.1093/annonc/mdn554. Epub 2008 Aug 9.

PMID:
18689864
20.

Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry SM, Pirih FQ, Aghaloo TL, Tetradis S.

J Bone Miner Res. 2013 Jul;28(7):1631-40. doi: 10.1002/jbmr.1894.

Supplemental Content

Support Center